Recs

2
Player Avatar TSIF (99.96) Submitted: 4/8/2014 6:11:28 PM : Outperform Start Price: $11.20 IPHYF Score: +5.47

Porte favorite, being erratic...with biopharm "derisking" by the markets..
MARSEILLE, France
Long road to go.
Expanding trials Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab (anti-KIR) and nivolumab (anti-PD-1) in selected solid tumors.

lirilumab licened by Bristol-Myers and funding phase 1....a solid partner...
Additional pipeline of two more candidates one also Bristol-Myers Squibb and one Novo Nordisk A/S.

Watching for now......

Featured Broker Partners


Advertisement